Paris, France and Camberley, UK – 12 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to provide an update regarding the novel coronavirus (COVID-19) test developed by Primerdesign, its molecular diagnostics division, and announces it has invested in a significant increase in manufacturing capacity to support the growing demand for its COVID-19 test.
http://novacyt.com/wp-content/uploads/2020/03/Novacyt-Covid-19-test-update-ENGLISH-12.03.2020.pdf